Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  228.43
+1.08 (0.48%)
AAPL  270.97
-2.70 (-0.99%)
AMD  214.95
+1.52 (0.71%)
BAC  55.88
+0.61 (1.10%)
GOOG  311.33
+2.72 (0.88%)
META  661.50
+2.73 (0.41%)
MSFT  484.92
-1.00 (-0.21%)
NVDA  183.69
+2.70 (1.49%)
ORCL  198.38
+6.41 (3.34%)
TSLA  488.73
+7.53 (1.56%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.